Pfizer (PFE) Tops Q1 EPS by 3c, Beats on Revenue; Offers FY26 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance
May 5, 2026 6:45 AM EDTEarnings Driven by Focused Execution and 22% Op Revenue Growth of Launched and Acquired Products(1) Pipeline Momentum Builds on Positive Phase 3 and Mid-Stage Readouts Robust LateStage R&D Pipeline, On Track to Start ~20 Key Pivotal Studies in 2026
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2026 and reaffirmed its full-year 2026 financial guidance(2).
EXECUTIVE COMMENTARY
Dr. Albert Bourla, Chairman and CEO of Pfizer:
We're off to a strong start in... More
